The festive season is almost upon us once again. Since many British and other European folk (not to mention our American cousins) are feeling somewhat exhausted by the political upheavals that 2016 has brought with it, the Kluwer patents team thought that there could be few better ways to take one’s mind off the current turmoil than with a Christmas quiz on second medical use patents.


Try and complete the quiz without looking anything up.  Also, since questions 11 and 12 relate to matters of opinion, your answers will not count towards the total which will be marked out of 10.   All correct entries will go into a hat and the draw for the prize (a copy of Buehling’s Patent Protection for Second Medical Uses is on offer) will be made on Monday 9 January 2017.  We will publish the name of the lucky winner (assuming he or she does not demand anonymity), the correct answers, and the findings of questions 11 and 12 shortly thereafter.

Good luck!

Welcome to your Kluwer Christmas SMU Quiz

1) What is the EPO Case Number of the EISAI case in which Swiss-type claims were first adopted by the EPO?
2) What was unusual about the composition of the English Patents Court in the John Wyeth case in 1985?
3) What is the correct term for manifest preparation in German?
4) What is T1780/12 most famous for?
5) When is the UK Supreme Court scheduled to hear the appeal in the pemetrexed case?
6) In which city was AIPPI Resolution 238 (on second medical use patents) passed?
7) Which Court issued the decision in the Lyrica patent infringement preliminary injunction proceedings in Germany?
8) True or False, in October 2015 Pfizer was successful in obtaining a preliminary injunction against Sandoz following launch of its carved out pregabalin medicine in France?
9) What was the composition of the Dutch Court of Appeal in the Novartis v Sun case which adjudged Sun to have indirectly infringed Novartis dosage regimen patent for zoledronic acid in the treatment of osteoporosis?
10) How many defendants were there to the Danish action brought by Warner-Lambert and Pfizer in relation to Krka’s generic pregabalin in 2015?
11) In your opinion, what is the best analysis of the construction of Swiss-type claims?
12) In your opinion, what should generics companies have to do in order to ensure that their product is not used for the patented indication?



To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law